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Abstract
Objective: Juvenile Systemic Lupus Erythematosus (SLE) varies by location and ethnicity. This study describes the
clinical, laboratory profile and outcome of juvenile SLE seen at Philippine General Hospital (PGH) from 2004-2008.
Method: Medical charts of all Filipino Juvenile SLE cases admitted at PGH during the 5-year period were reviewed
collecting demographic profile, clinical and laboratory manifestations and treatment during disease course.
Results: Seventy-eight cases of juvenile SLE were reviewed. There were 7 boys and 71 girls. The mean age at
diagnosis was 14 years (SD 2.7) with a range of 8-18 years. Fever (52.5%) and malar rash (41.0%) were the most
common features at disease onset. At the time of diagnosis, the most common features were malar rash (65.3%),
renal involvement (62.8%) and photosensitivity (55.1%). Mucocutaneous (92.3%), renal (71.7%) and hematologic
(69.2%) involvement were the most common features during the entire course of illness. Infection (34.5%) and
neurologic (19.0%) complications were observed most frequently. Corticocosteroid treatment was given in most of
the patients in the form of prednisone (97.4%) and concomitant methylprednisolone intravenous pulses (29.4%).
Nine patients died during the study period. The overall 5-year mortality rate was 11.5%. Infection (77.0%) was the
most frequent cause of death.
Conclusion: Malar rash was a common feature at disease onset and at diagnosis among Filipinos with juvenile
SLE. Throughout the disease course, renal involvement occurs in 71.7% of patients. Infection was the leading cause
of complication and death. The clinical presentations of Filipinos with juvenile SLE were similar to juvenile SLE in
other countries.
Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune
disease characterized by widespread inflammation of
blood vessels and connective tissues and by the presence
of antinuclear antibodies (ANAs), especially antibodies
to native double stranded DNA (Anti dsDNA). Its clini-
cal manifestation is variable and its natural history is
unpredictable. Incidence of juvenile SLE varies by loca-
tion and ethnicity. There is a wide range of variation in
the natural history of SLE among different ethnic and
geographical groups. Studies in juvenile SLE have esti-
mated the incidence at 0.28 to 0.9/100,000 per year
[1-3]. A previous study done by Brunner et al in 2008
among Caucasians suggests that patients with child-
hood-onset SLE have more active disease upon
presentation and over time than adults. Children
received more intensive drug therapy and accrue more
damage [4]. Two significant factors with poor prognosis
are female gender and development of end-stage renal
disease (ESRD) [5]. Organ damage was significantly
more likely to occur in patients who experienced neu-
ropsychiatric manifestations upon diagnosis, had longer
disease duration, and had received more intravenous
pulses of cyclophosphamide [6]. Recurrent major infec-
tions significantly correlate with poorer long-term organ
damage [7].
The actual prevalence of juvenile SLE among Filipinos
is still unknown. With the review of the clinical mani-
festations of SLE cases and increased awareness of this
condition in pediatric patients, this study hopes to be of
value in ensuring early recognition and early institution
of appropriate management of this often missed
and mismanaged condition. We chose to review cases
at the Philippine General Hospital (PGH), a tertiary
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the Filipino people’s national university hospital and
premier referral center. It caters more for low-income
patients and it is the only institution in the country with
a Pediatric Rheumatology training program.
This retrospective study aims to describe the clinical,
laboratory profile and outcome of juvenile SLE seen at
the PGH during a 5-year period from January 2004 to
December 2008.
Methodology
Patients diagnosed with juvenile SLE (met > 4 criteria
of the 1997 revised American College of Rheumatol-
ogy [ACR] classification criteria for SLE); age at
onset <18 years according to the Paediatric Rheuma-
tology International Trials Organization (PRINTO)
[8] were included in the study. Patients were identi-
fied from the Out-patient and In-patient (wards and
emergency room) service of General Pediatrics,
Pediatric Rheumatology and Pediatric Nephrology
sections of PGH. The institutional review board
approved the study.
Medical charts were retrieved from the records section
of PGH by the primary investigator (CG). These were
reviewed from the date of the initial consult up to the
last date of follow up. A data collection form was used
to collect information on demographic profile, present-
ing features, clinical and laboratory manifestations and
treatment during the course of the disease for each
patient.
Clinical presentation at onset of disease was defined as
the manifestations at the first 3 months of illness. The
time of diagnosis was defined as the time when the
patient fulfilled at least four ACR 1997 revised classifica-
tion criteria for SLE.
Records of clinical and laboratory findings during the
study period were collected as follows: Hemolytic ane-
mia with reticulocytosis, leucocytopenia (< 4000 cells/
mm3) and lymphopenia [absolute lymphocytic count
(ALC) <1,500 cells/mm
3 ]p r e s e n ti n2o rm o r eo c c a -
sions, thrombocytopenia (< 100,000 cells/mm
3)i nt h e
absence of offending drugs, abnormal urinalysis (protei-
nuria 0.5 g/24 h or >3+ if quantitative evaluation was
not done, and/or casts, hematuria >5 RBCs/HPF or
pyuria >5 WBCs/HPF in the absence of infection),
increased creatinine (> 1 mg/dl), low C3, increased ery-
throcyte sedimentation rate (ESR) (> 20 mm/hr). Pleuri-
tis documented by history of pleuritic pain or rub heard
by physician or evidence of pleural effusion and pericar-
ditis documented by ECG, rub, or evidence of pericar-
dial effusion. Growth failure is defined as the presence
of at least 2 of the following 3 features: 1) height below
the third percentile for age; 2) growth velocity over
6 months below the third percentile for age; 3) crossing
at least 2 percentiles (5%,10%, 25%, 50%, 75%, 95%) on
National Center for Health Statistics growth charts.
Delayed puberty is defined as a delay in development of
secondary sexual characteristics more than 2 SD below
the mean for age by Tanner staging. Complications and
causes of death were analyzed. Descriptive statistics
which include mean, median, range and frequency were
computed.
Results
Of the 84 children diagnosed with juvenile SLE seen
in our institution, 78 of them (93.0%) had available
medical records for review. The female to male ratio
was 10:1 (71 girls, 7 boys). The overall mean age at
diagnosis was 14.0 years (SD 2.7) (boys 13.7 years,
girls 14.0 years), with a range of 8-18 years. The peak
age group on diagnosis is 11 year old for male and
17 year old for female patients. Eight (10.2%) of our
Filipino juvenile SLE patients are known to have history
of SLE in the family. Six of them were first-degree
relatives.
Clinical and Laboratory Features
Fever (52.5%), malar rash (41.0%), oral/nasopharyngeal
ulcers (29.4%), alopecia and general fatigue (28.2%)
were the most common features at disease onset (see
Table 1).
At the time of diagnosis, the most common features
were malar rash (65.3%), renal involvement (62.8%) and
photosensitivity (55.1%) (see Table 2). Cardiovascular
involvement was found in 17.0% of patients, pericardial
effusion was noted in 15.3% and valvular anomaly
10.2%. They presented with tricuspid regurgitation (5),
pulmonary regurgitation (2), mitral regurgitation (2) and
moderate aortic regurgitation (1). Hematologic manifes-
tations were as follows: 58.0% had anemia (hemoglobin
range: 3.6-11.8; median: 9.35; mean 8.86 SD 2.02 g/dl),
8.9% with positive Coombs test, 15.3% with leukocyto-
penia (range: 2,950-3,900; median 3,800 cell/mm
3),
21.7% with lymphocytopenia (ALC range: 325-1,431;
median 1,034 cells/mm
3), 14.1% with thrombocytopenia
(platelet count range: 27,000-90,000; median 56,000
cells/mm
3).
Mucocutaneous (92.3%), renal (71.7%) and hematolo-
gic (69.2%) involvement were the most common features
during the entire course of illness(see Table 2).
ANA was positive in 98.5% (n = 70/71) of our patients,
mostly done using Indirect Immunofluorescence (IIF)
technique using HEp-2 cells (70.0%). LE cell could
be demonstrated in 25.6% of patients. Anti-dsDNA
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was done in only 21 patients and titers were significantly
high among 18 of them.
The frequency of complications in our juvenile SLE
patients is shown in Table 3. Infection (34.5%) followed
by neurologic (19.0%) and musculoskeletal (8.7%) were
observed most frequently.
Throughout the study period, 71.7% (56/78) of
patients had renal involvement. Renal biopsy was done
only among 24 of these patients. Evaluation was based
on WHO classification for lupus nephritis. One was
found to be of mixed type and was then classified under
the dominant class. Renal histology showed class II
nephritis in 25.0%, class III in 20.8%, class IV in 50.0%
and class V in 4.1%.
Therapy
Corticosteroid treatment was given in most of the
patients in the form of prednisone (97.4%) and
Methylprednisolone IV pulses (29.4%). Hydroxychloro-
quine was used in 32.0%, Azathioprine in 23.0%, Cyclo-
phosphamide intravenous pulses in 26.9%.
Clinical Outcomes
The follow-up period ranged from 0.1-6.4 years with a
mean duration of 1.7 years (SD 1.8). About 34.6% of the
Filipino juvenile SLE patients seen our institution are
still attending our clinics, 21.7% were endorsed to adult
Table 2 Clinical and Laboratory Features among 78
juvenile SLE patients
Category At the time of
diagnosis
during the disease
course
No. % No. %
Mucocutaneous
Manifestations
71 91.0 72 92.3
Malar rash 51 65.3 60 76.9
Discoid rash 25 32.0 28 35.8
Photosensitivity 43 55.1 57 73.0
Oral ulcers 42 53.8 53 67.9
Alopecia 31 39.7 41 52.5
Musculoskeletal
Involvement
32 41.0 42 53.8
Arthritis 17 21.7 31 39.7
Arthralgia 24 30.7 40 51.2
Pulmonary Involvement 11 14.1 17 21.7
Pleuritis/Pleural effusion 11 14.1 16 20.5
Cardiac Involvement 13 16.6 17 21.7
Pericarditis/Pericardial
Effusion
12 15.3 14 20.5
Valvular anomaly on
Echocardiography
8 10.2 8 10.2
Ventricular/atrial
Hypertrophy
4 5.1 5 6.4
Renal involvement 49 62.8 56 71.7
Hematuria 19 24.3 26 33.3
Proteinuria 32 41.0 20 25.6
CNS involvement 24 30.7 25 32.0
Seizure 12 15.3 15 19.2
Behavioral changes 9 11.5 10 12.8
Hematologic
Involvement
37 47.4 54 69.2
Laboratory
Cellular casts 11 14.1 22 28.2
Increased creatinine 6 7.6 11 14.1
Hemolytic anemia 7 8.9 8 10.2
Leukocytopenia 12 15.3 25 32.0
Lymphocytopenia 17 21.7 32 41.0
Thrombocytopenia 11 14.1 20 25.6
Low C3 7 8.9 7 8.9
Table 1 Presenting features at Disease Onset among 78
juvenile SLE patients
Manifestation No. %
Mucocutaneous
Malar rash 32 41.0
Oral/nasopharyngeal ulcers 23 29.4
Alopecia 22 28.2
Photosensitivity 19 24.0
Punctate erythema 7 8.9
Discoid rash 5 6.4
Epistaxis 5 6.4
Gumbleeding 2 2.5
Musculoskeletal
Arthralgia 21 26.9
Arthritis 14 17.9
Haematologic
Pallor 16 20.5
Neuropsychiatric
Seizures 3 3.8
Psychiatric symptoms 2 2.5
Renal
Gross hematuria 9 11.5
Gastrointestinal
Abdominal pain 7 8.9
Vomiting 7 8.9
Constitutional
Fever 41 52.5
General fatigue 22 28.2
Weight loss 14 17.9
Loss of appetite 7 8.9
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while 25.6% were lost to follow-up.
Nine patients died during the five-year study period.
The causes of death were (1) active lupus (acute renal
failure), (1) severe pulmonary hypertension and (7)
infection. Identified pathogens on blood culture were
Pseudomonas aeroginosa, Methicillin-resistant Staphylo-
coccus epidermidis, Burkholderia mallei and Klebsiella
pneumoniae. One had concomitant staphylococcal pneu-
monia and the other with osteomyelitis secondary to
Salmonella sp (documented by synovial fluid culture).
Discussion
We compared the manifestations at diagnosis as well as
the cumulative features of our juvenile SLE patients
with the local data as well as from other countries (see
Table 4 and 5). Available literatures with hospital-based
data on juvenile SLE were included.
In our series, mean age at diagnosis was at 14.0 (SD
2.7) years old which is comparable to other studies
(see Table 5). We reported 8 yr old as the youngest
age at initial SLE diagnosis. This is relatively old com-
pared to other series with reported youngest age at 2
to 7 years old [9-12]. Female preponderance, similar
from reports of other countries, emphasizes the impor-
tance of hormonal factors in the clinical expression of
the disease.
All local studies showed malar rash as the most com-
mon clinical feature at the time of diagnosis as well as
during the entire course of illness [12,13]. Our patients
had fewer reports of arthritis but a significantly higher
neuropsychiatric manifestations compared to the other
local study done by Hamijoyo[12,13] as well as with that
of Taiwan [5] and Egypt [9]. The frequency of renal
involvement in our study (62.8%) was comparable to the
studies from Taiwan (58.8%) [5] and Trinidad (63.6%)
[10]. Among the clinical features found throughout the
entire clinical course, the cumulative frequency of hema-
tologic (69.2%) and neuropsyschiatric (32%) involvement
in our series is comparable to other studies [9,13-16].
However, arthritis still remained low throughout the
course of illness in our patient population compared to
other studies [13,14,16,17]. The cumulative frequency of
renal involvement in our series (71.7%) is comparable to
studies involving Arab (65%) [14] and Egyptian (67%)
[5] children but more common than in Canadian
(55.0%) [17], European (62.5%) [18], African-American
(44.0%) [15] and Latin American children (55%) [15].
Wide variations among different studies may be attribu-
ted to genetic differences or to referral bias, as some
studies came from nephrology units and others from
rheumatology units.
Most of our patients with lupus nephritis had patholo-
gical changes consistent with Class III and IV lupus
nephritis (WHO classification). Report of nephritis was
highest in Thailand (86.2%)[16] and lowest in African-
American children(44%)[15]. These diverse presentations,
disease course and outcome appear to be multifactorial.
Environmental, socioeconomic, demographic, psychoso-
cial, genetic (HLA-DRBl*0301, HLA-DRB1, FCGR gene
family, IRF5, STAT4 and MECP2) [19], and clinical
factors play an important role as determinants of the eth-
nic differences [20]. Further investigation is needed to
elucidate the basis of these disparities.
One of the limitations of this study was that not all
patients were able to have the complete antibody profile
and kidney biopsy. This was primarily due to financial
reasons as majority of our patients came from low
income families.
Table 3 Complications among 78 juvenile SLE patients
Item N %
Infection 27 34.5
Pneumonia 11 14.1
Sepsis 8 10.2
Tuberculosis (pulmonary, endotracheal, miliary) 6 7.7
Cellulitis 2 2.5
Neurologic 15 19.0
Seizure requiring therapy for 6 months 12 15.3
Cerebral atrophy by imaging (Cranial CT scan) 2 2.5
Lateral rectus palsy 1 1.2
Musculoskeletal 5 8.7
Deforming or erosive arthritis 3 3.8
Osteoporosis with fracture or vertebral collapse 2 2.5
Osteomyelitis 1 1.2
Muscle atrophy or weakness 1 1.2
Skin 4 5.0
Scarring chronic alopecia 2 2.5
Extensive scarring or panniculum other than scalp and
pulp space
2 2.5
Gastrointestinal 2 2.0
Autoimmune hepatitis by biopsy 2 2.0
Renal 2 2.5
Estimated or measured glomerular filtration rate < 50% 2 2.5
Growth failure 4 5.1
Pubertal delay 2 2.5
Ocular 1 1.2
Ischemic retinopathy 1 1.2
Pulmonary 1 1.2
Pulmonary hypertension 1 1.2
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was infection (77%). The identified pathogens included
were mostly gram negative bacteria. Nosocomial infec-
tion was the predominant type. This was similar in most
studies on juvenile SLE, as infection has replaced renal
failure as the leading cause of mortality among these
patients [5,21-23]. Use of immunosuppressive therapy
and inherent immune abnormalities in active lupus pre-
disposes these children to infection. However, a major
contributory factor which probably caused such high
mortality in our institution could be that most of our
patients belong to the low income families contributing
to poor treatment compliance and adherence and poor
follow-up. Another potential factor could be that our
patients might have more severe disease spectrum since
we are the biggest government institution with a referral
center for children with rheumatologic diseases. Faced
with such obstacles, a stronger awareness and recogni-
tion of this condition by other health professionals
hopefully would assure early referral to the pediatric
rheumatologist and other appropriate subspecialists.
Emphasis in programs for health promotions among
chronically ill patients and access support group for
Filipino children suffering from lupus should also be
advocated.
Conclusion
Malar rash was a common feature at disease onset and at
diagnosis among Filipinos with juvenile SLE. Throughout
the disease course, renal involvement occurs in 71.7%
of patients. Infection was the leading cause of complica-
tion and death. The clinical presentations of Filipinos
Table 4 Clinical And Laboratory Variables Of Children With SLE At Diagnosis Compared To Other Countries
Present Study Wang, 2003
5 Balkaran, 2004
10 Bakr, 2005
11 Salah, 2009
9 Hamijoyo, 2009
12
No.of
Patients
78 153 33 52 207 147
Country Philippines Taiwan Trinidad Egypt Egypt Philippines
Follow-up, y
Mean
Range
1.7 ± 1.8
[0.1-6.4]
6.1 ± 9.0 1 ± 9.3
Age at diagnosis, y
Mean+SD
Range
14 ± 2.7
8-1 8
13.5 ± 5.5
5-17
11.9 ± 2.6
6-16
10 ± 2.7
2-1 6
12.29 ± 2.9
4-1 6
F:M ratio 10:1 5.9:1 6.6:1 12:1 2.69:1 11.2:1
Rash
Malar 65.3 77.1 39 46.2 74.8
Discoid 32.0 2.0 37 19.0
Photosensitivity 55.1 24.8 21,2 57.8
Oral ulcers 53.8 26.1 19.6 49.7
Alopecia 39.7 13.1 34.6 45.5 51.7
Musculoskeletal 53.8 69.7 65.4
Arthritis 21.7 57.5 46.9 61.9
Neuropsychiatric 30.7 4.6 7.7 7.2 8.2
Serositis 26.9 15 14.3
Pleural
Effusion
14.1 6.3
Pericardial
Effusion
15.3 7.7
Nephritis 62.8 58.8 63.6 80.8 20.8 48.3
Hematologic 51.2 79.7 38.8
Thrombocytopenia 14.1 19.6 29.2
Hemolytic
Anemia
8.9 44.4 17.0
Leukocytopenia 15.3 34.6 27.5
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countries.
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